Flu and COVID-19 Vaccination: What Happens to the Flu Shot When the Campaigns Overlap? Experience from a Large Italian Research Hospital.

Domenico Pascucci, Mario Cesare Nurchis, Alberto Lontano, Eleonora Marziali, Giuseppe Vetrugno, Andrea Cambieri, Umberto Moscato, Andrea Di Pilla, Gianfranco Damiani, Patrizia Laurenti
Author Information
  1. Domenico Pascucci: Università Cattolica del Sacro Cuore, 00168 Rome, Italy. ORCID
  2. Mario Cesare Nurchis: Università Cattolica del Sacro Cuore, 00168 Rome, Italy. ORCID
  3. Alberto Lontano: Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  4. Eleonora Marziali: Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  5. Giuseppe Vetrugno: Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  6. Andrea Cambieri: Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
  7. Umberto Moscato: Università Cattolica del Sacro Cuore, 00168 Rome, Italy. ORCID
  8. Andrea Di Pilla: Università Cattolica del Sacro Cuore, 00168 Rome, Italy. ORCID
  9. Gianfranco Damiani: Università Cattolica del Sacro Cuore, 00168 Rome, Italy. ORCID
  10. Patrizia Laurenti: Università Cattolica del Sacro Cuore, 00168 Rome, Italy. ORCID

Abstract

influenza represents a threat to global health and health care workers (HCWs) have an increased risk of contracting the influenza virus in the workplace. The COVID-19 pandemic has brought back the importance of influenza vaccination, as the influenza virus can circulate together with SARS-CoV-2. The aim of this report is to describe the actual flu vaccination coverage among healthcare workers of a research hospital and the trend changes, with respect to the past flu vaccination campaigns, in light of the present pandemic and COVID-19 vaccination. A Pearson’s χ2 test was used to test the correlation of flu vaccination coverage, across all professional categories, between the last two years. A linear regression model was adopted to predict the total vaccination coverage of this year. A statistically significant decrease (p < 0.01) was observed in vaccination coverage among all the professional categories with a 50% reduction in vaccination trends between the last two years. Analyzing the data from the previous six flu vaccination campaigns, the expected value, according to the linear regression model, was estimated to be 38.5% while the observed value was 24%. The decrease in vaccination coverage may be due to the fear of the pandemic situation and especially to the uncertainty related to the consequences of a concurrent administration which may overload the immune system or may be more reactogenic. The COVID-19 pandemic represents an opportunity to promote and support large-scale influenza vaccination among HCWs through structured programs, adequate funding, and tailored communication strategies.

Keywords

References

  1. Public Health. 2018 Jan;154:102-109 [PMID: 29220709]
  2. Hum Vaccin Immunother. 2020;16(2):321-326 [PMID: 31526228]
  3. Pharmaceuticals (Basel). 2022 Mar 08;15(3): [PMID: 35337120]
  4. Vaccines (Basel). 2020 Feb 13;8(1): [PMID: 32069869]
  5. J Hosp Infect. 2021 Jun;112:45-48 [PMID: 33746009]
  6. Infection. 2009 Jun;37(3):197-202 [PMID: 19139807]
  7. Clin Infect Dis. 2006 Apr 15;42(8):1141-3 [PMID: 16575732]
  8. Vaccines (Basel). 2020 Sep 16;8(3): [PMID: 32947988]
  9. BMJ. 2020 Sep 23;370:m3720 [PMID: 32967850]
  10. Infect Control Hosp Epidemiol. 2008 Jan;29(1):89-91 [PMID: 18171197]
  11. Hum Vaccin Immunother. 2019;15(4):967-972 [PMID: 30543134]
  12. Expert Rev Vaccines. 2021 Aug;20(8):919-920 [PMID: 33985390]
  13. Med Decis Making. 1999 Apr-Jun;19(2):193-201 [PMID: 10231082]
  14. Vaccine. 2019 Oct 8;37(43):6255-6261 [PMID: 31500965]
  15. Vaccine. 2015 Mar 24;33(13):1625-8 [PMID: 25678243]
  16. Hum Vaccin. 2011 Jul;7(7):728-33 [PMID: 21705859]
  17. Vaccine. 2016 Sep 22;34(41):5013-5020 [PMID: 27576074]
  18. Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76 [PMID: 23210147]
  19. Vaccine. 2020 Oct 21;38(45):7049-7056 [PMID: 32980199]
  20. Hum Vaccin Immunother. 2020;16(1):81-85 [PMID: 31210582]
  21. Int J Environ Res Public Health. 2021 Dec 11;18(24): [PMID: 34948694]
  22. Vaccines (Basel). 2021 Mar 18;9(3): [PMID: 33803755]
  23. Hum Vaccin Immunother. 2021 Aug 3;17(8):2719-2722 [PMID: 33844618]
  24. Vaccines (Basel). 2019 Dec 26;8(1): [PMID: 31887994]
  25. Clin Microbiol Infect. 2012 May;18(5):E137-9 [PMID: 22404767]
  26. Infect Control Hosp Epidemiol. 2013 Nov;34(11):1194-200 [PMID: 24113604]
  27. Hum Vaccin Immunother. 2021 Oct 3;17(10):3662-3669 [PMID: 34129422]
  28. Vaccine. 2009 May 5;27(20):2631-2 [PMID: 19428870]
  29. BMC Nurs. 2017 Apr 28;16:20 [PMID: 28465672]
  30. Early Hum Dev. 2020 Sep;148:105116 [PMID: 32604011]
  31. Hum Vaccin Immunother. 2016 Mar 3;12(3):671-81 [PMID: 26619125]
  32. Hum Vaccin Immunother. 2021 Jul 3;17(7):2185-2189 [PMID: 33497309]
  33. J Hosp Infect. 2012 Apr;80(4):316-20 [PMID: 22336083]
  34. Hum Vaccin Immunother. 2014;10(5):1204-10 [PMID: 24603089]
  35. Euro Surveill. 2013 Nov 07;18(45):20627 [PMID: 24229791]
  36. Euro Surveill. 2021 Jul;26(26): [PMID: 34212841]
  37. Infect Control Hosp Epidemiol. 2007 Feb;28(2):171-7 [PMID: 17265398]
  38. BMJ. 2008 Oct 28;337:a2140 [PMID: 18957465]
  39. Hum Vaccin Immunother. 2021 Nov 2;17(11):4623-4631 [PMID: 34292126]
  40. PLoS One. 2021 Nov 19;16(11):e0260213 [PMID: 34797861]
  41. Eur J Public Health. 2011 Jun;21(3):329-32 [PMID: 20833841]
  42. Lancet. 2021 Dec 18;398(10318):2277-2287 [PMID: 34774197]
  43. Hum Vaccin Immunother. 2018 Mar 4;14(3):772-789 [PMID: 28787234]
  44. Int J Environ Res Public Health. 2021 May 30;18(11): [PMID: 34070763]
  45. Int J Evid Based Healthc. 2011 Dec;9(4):403-19 [PMID: 22093389]
  46. Infect Control Hosp Epidemiol. 2004 Nov;25(11):923-8 [PMID: 15566025]
  47. Hum Vaccin Immunother. 2017 Feb;13(2):470-476 [PMID: 27924688]
  48. Isr J Health Policy Res. 2016 Oct 26;5:52 [PMID: 27800154]
  49. Hum Vaccin Immunother. 2021 Nov 2;17(11):4611-4616 [PMID: 34542384]
  50. Vaccine. 2018 May 31;36(23):3351-3358 [PMID: 29716777]
  51. Vaccine. 2008 May 12;26(20):2482-9 [PMID: 18407385]
  52. Hum Vaccin Immunother. 2022 Dec 31;18(1):1978795 [PMID: 34613881]
  53. Int J Environ Res Public Health. 2022 Jan 30;19(3): [PMID: 35162609]
  54. Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5529-5541 [PMID: 34533803]
  55. Influenza Other Respir Viruses. 2013 Jul;7(4):604-21 [PMID: 22984794]
  56. Eur J Med Res. 2010 Nov 4;15 Suppl 2:235-40 [PMID: 21147658]
  57. Heliyon. 2019 Oct 12;5(10):e02604 [PMID: 31667418]

Word Cloud

Created with Highcharts 10.0.0vaccinationcoverageCOVID-19fluinfluenzapandemichealthworkersamongmayrepresentsHCWsvirushealthcarecampaignstestprofessionalcategorieslasttwoyearslinearregressionmodeldecreaseobservedvalueFluInfluenzathreatglobalcareincreasedriskcontractingworkplacebroughtbackimportancecancirculatetogetherSARS-CoV-2aimreportdescribeactualresearchhospitaltrendchangesrespectpastlightpresentPearson’sχ2usedcorrelationacrossadoptedpredicttotalyearstatisticallysignificantp<00150%reductiontrendsAnalyzingdataprevioussixexpectedaccordingestimated385%24%duefearsituationespeciallyuncertaintyrelatedconsequencesconcurrentadministrationoverloadimmunesystemreactogenicopportunitypromotesupportlarge-scalestructuredprogramsadequatefundingtailoredcommunicationstrategiesVaccination:HappensShotCampaignsOverlap?ExperienceLargeItalianResearchHospitalpublic

Similar Articles

Cited By (11)